Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings

Journal of Comparative Effectiveness Research

Volumn 1, Issue 2, 2012, Pages 157-170

  Castillo Mancilla, Jose R ^a   Campbell, Thomas B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

atazanavir; efavirenz; lopinavir ritonavir; nevirapine; protease inhibitor; resource limited setting; treatment naive

Indexed keywords

ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER DISEASE; MENTAL DISEASE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; TUBERCULOSIS;

EID: 84880721582     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.12.6     Document Type: Review

References (37)

1. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin. Drug Metab. Toxicol. 6(1), 95-103 (2010).
2. Matteelli A, Regazzi M, Villani P et al. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr. HIV Res. 5(3), 349-353 (2007).
3. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur. J. Contracept. Reprod. Health Care 13(2), 123-132 (2008).
4. Thompson MA, Aberg JA, Cahn P et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3), 321-333 (2010).
5. Ayala Gaytan JJ, Zapata de la Garza ER, Chavez Garcia M, Valdovinos Chavez SB. Nevirapine or efavirenz in combination with two nucleoside analogues in HIV-infected antiretroviral-naive patients. Med. Int. Mex. 20(1), 29-33 (2004).
6. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
7. Sow PG, Badiane M, Diallo PD, Lo I, Ndiaye B, Gaye AM. Efficacy and safety of lamivudine+zidovudine+efavirenz and lamivu dine+zidovudine+nevirapine in treatment of HIV 1 infected patients. A retrospective cross study analysis. Presented at: XVI International AIDS Conference. Toronto, Canada, 13-18 August 2006 (Abstract CDB0584).
8. Campbell T, Smeaton L, De Grutolla V et al. PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/ lamivudine and efavirenz for initial treatment of HIV 1 infection. Presented at: XVII International AIDS Conference. Mexico City, Mexico, 3-8 August 2008 (Abstract THAB0404).
9. Manosuthi W, Sungkanuparph S, Tantanathip P et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin. Infect. Dis. 48(12), 1752-1759 (2009).
10. Wester CW, Thomas AM, Bussmann H et al. Non-nucleoside reverse-transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS 24(Suppl. 1), S27-S36 (2010).
11. Sierra-Madero J, Villasis-Keever A, Méndez P et al. Prospective, randomized, open label trial of efavirenz vs lopinavir/ritonavir in HIV+ treatment-naive subjects with CD4+ 200 cell/mm3 in Mexico. J. Acquir. Immune Defic. Syndr. 53(5), 582-588 (2010).
12. Ratsela A, Polis M, Dhlomo S et al.; Phidisa II Writing Team for Project Phidisa. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count 200 cells/?l in South Africa. J. Infect. Dis. 202(10), 1529-1537 (2010).
13. Swaminathan S, Padmapriyadarsini C, Venkatesan P et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin. Infect. Dis. 53(7), 716-724 (2011).
14. Bonnet M, Bhatt N, Baudin E et al. CARINEMO study group Results of the CARINEMO-ANRS 12,146 randomized trial comparing the efficacy and safety of nevirapine versus efavirenz for treatment of HIV-TB co-infected patients in Mozambique. Presented at: 6th IAS Conference on HIV pathogenesis, Treatment and Prevention. Rome, Italy, 17-20 July 2011 (Abstract ELBX05).
15. AMMVIH. [Guidelines for the use of antiretroviral medications in patients with HIV/AIDS.] Mexican Medical Association for HIV/AIDS, AC México (2002).
16. Robbins GK, De Gruttola V, Shafer RW et al. AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV 1 infection. N. Engl. J. Med. 349(24), 2293-2303 (2003).
17. Núñez M, Soriano V, Martín-Carbonero L et al. SENC (Spanish efavirenz vs nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin. Trials 3(3), 186-194 (2002).
18. van den Berg-Wolf M, Hullsiek KH, Peng G et al.; the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), The International Network for Strategic Initiative in Global HIV Trials (INSIGHT). Virologic, immunologic, clinical, safety and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV 1-infected persons. HIV Clin. Trials 9(5), 324-336 (2008).
19. Gulick RM, Ribaudo HJ, Shikuma CM et al.; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV 1 infection. N. Engl. J. Med. 350(18), 1850-1861 (2004).
20. Gallant JE, Rodriguez AE, Weinberg WG et al. ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192(11), 1921-1930 (2005).
21. Riddler SA, Haubrich R, DiRienzo AG et al. AIDS Clinical Trials Group Study A5142 Team Class-sparing regimens for initial treatment of HIV 1 infection. N. Engl. J. Med. 15(20), 2095-2106 (2008).
22. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV 1 infection in adults. Study 006 Team. N. Engl. J. Med. 341(25), 1865-1873 (1999).
23. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36(5), 1011-1019 (2004).
24. Lennox JL, DeJesus E, Lazzarin A et al.; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV 1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374(9692), 796-806 (2009).
25. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV 1 infection. J. Infect. Dis. 201(6), 803-813 (2010).
26. Andrade A, Baheti G, Smeaton L et al.; ACTG PEARLS A5175 Study Team. Sex- and geographic-based differences in ATV pharmacokinetics in subjects treated with ddI-EC, FTC, and ATV in the ACTG PEARLS Study. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 648).
27. Mbanya D, Assah F, Ndembi N, Kaptue L. Monitoring antiretroviral therapy in HIV/ AIDS patients in resource-limited settings: CD4 counts or total lymphocyte counts? Int. J. Infect. Dis. 11(2), 157-160 (2007).
28. Hoffmann CJ, Charalambous S, Sim J et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin. Infect. Dis. 49(12), 1928-1935 (2009).
29. Hodder SL, Mounzer K, Dejesus E et al. AI266073 Study Group. Patient-reported outcomes in virologically suppressed, HIV 1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 24(2), 87-96 (2010).
30. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 24(18), 2835-2840 (2010).
31. Bussmann H, Wester CW, Wester CN et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J. Acquir. Immune Defic. Syndr. 45(3), 269-273 (2007).
32. Rossouw T. Quantifying antiretroviral risk in pregnancy. S. Afr. Med. J. 97(11), 1014-1016 (2007).
33. Patel D, Thorne C, Fiore S, Newell ML. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J. Acquir. Immune Defic. Syndr. 40(1), 116-118 (2005).
34. Laher F, Forrest J, Mohapi L, Gray G. Efavirenz conceptions in Soweto, South Africa. Presented at: The 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa, 19-22 July 2009 (Abstract 1121).
35. German P, Greenhouse B, Coates C et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44(6), 889-891 (2007).
36. van Heeswijk R, Vandevoorde A, Boogaerts G et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 119).
37. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 118).